Michael Dey, Ph.DCEO of Predictive Therapeutics / Director

Michael Dey, Ph.D. is a member of the Board of Directors of Predictive Technology Group, Inc. Dr. Dey will assist in corporate governance and guide the development and commercialization of technology and products in all PRED’s subsidiaries.

In addition to serving as a PRED Board Member, Dr. Dey will continue as Chief Executive Officer of Predicitive Therapeutics, Inc., a wholly owned subsidiary of PRED. Before joining PRED, Dr. Dey had executive positions at Wyeth, later acquired by Pfizer, where he was both the President and the President of Scientific Affairs division for Wyeth’s Women’s Health Care business. As President of Wyeth’s Women’s Health Care business for seven years, Dr. Dey managed its global resources of more than $3 billion annually.

Dr. Dey received an undergraduate degree in Biology/Chemistry in 1973, a Master’s Degree in 1980 in Pharmacology and Toxicology and a Ph.D. in 1984 in Pharmacology and Toxicology

 

Timothy W. LacyChief Sales Officer

As a proven leader in the healthcare industry for over 27 years, Tim now serves as one of Predictive’s leaders. Playing a key role in the overall commercialization of Predictive Biotech and Predictive Therapeutics, he’s driving the evolution of a new product, marketing and sales approach across the healthcare continuum.

Before bringing his talents to Predictive, Tim served as a senior executive for Fortune 100 companies UnitedHealth Group and Walgreens for 20 years, where he managed national sales, sales operations and corporate development.

 

Dr. John C. Nelson. M.D., M.P.HChief Medical Officer

Dr. Nelson an obstetrician and gynecologist from Salt Lake City, Utah, brings a wealth of experience to PRED. Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine.

Dr. Nelson served as President of the American Medical Association, Salt Lake County Medical Society, and the Utah Medical Association. Also, he chaired the Finance and Planning Committee of the World Medical Association. He served on the Advisory Committee to the Director of the National Institutes of Health (NIH), as well as, on the advisory committee for the Agency for Healthcare Research and Quality (AHRQ). As a spokesperson for the American Medical Association Alliance, he lectured on detecting and preventing interpersonal violence. Dr. Nelson became a charter member of the Prospective Payment Assessment Commission (ProPAC), now known as MedPAC.

Dr. Nelson received numerous awards, among which are the Alumnus of the Year at Utah State University, the Distinguished Service Award from the University of Utah School of Medicine, the Emeritus Merit of Honor Award from the University of Utah Alumni Association, and the Light of Learning Award from the Utah Department of Education. As a founding co-chair of the Commission to End Healthcare Disparities, Dr. Nelson received a Lifetime Service Award from the National Medical Association.

 

John E. SorrentinoChairman of Scientific Advisory Board

John E. Sorrentino chairs the Predictive Therapeutics’ Scientific Advisory Board. Predictive Therapeutics, a wholly owned subsidiary of Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine. Sorrentino is Vice-President and Chief Operating Officer of Vaccine Research and Development at Pfizer and brings his vast experience in R&D and clinical laboratory management to the Predictive Therapeutics’ Advisory team.

Sorrentino has over 35 years of senior management experience in the life sciences. Focused on improving public health, he has held leadership roles in private, and public companies, as well as government and non-profit institutions. Prior to joining Wyeth, later acquired by Pfizer, 14 years ago, Sorrentino held executive positions in several organizations that provided neonatal screening and related clinical services. Sorrentino’s expertise has had him appear before state legislators, the US Congress and professional societies on a variety of healthcare and policy issues.

Mr. Sorrentino experiences in clinical testing and women’s health will be an invaluable addition to the Company’s current team of experts and its mission to effectively treat endometriosis

 

Dr. Hugh S. TaylorScientific Advisory Board

Dr. Taylor, a Chief of Obstetrics and Gynecology at Yale University, brings extensive clinical research and development expertise in endometriosis and women’s health to PRED’s Scientific Advisory Board team.

Dr. Taylor’s many accomplishments include Anita O’Keeffe Young Professor and Chairs Department of Obstetrics Gynecology and Reproductive Sciences at Yale School of Medicine and Chief of Obstetrics, and Gynecology at Yale-New Haven Hospital. He teaches as Professor of Molecular, Cellular and Developmental Biology at Yale University. His clinical interests include endometriosis, infertility, implantation, Asherman’s syndrome, menopause and uterine anomalies

.Also, Dr. Taylor, a board-certified specialist in Obstetrics and Gynecology and in Reproductive Endocrinology, received eight National Institutes of Health research grants. Dr. Taylor published more than 300 articles in leading medical journals, continues as the Editor-In-Chief of Reproductive Sciences, and elected to the membership of the National Academy of Medicine.

Dr. Taylor received his undergraduate training at Yale University and his medical degree from the University Of Connecticut School Of Medicine. He completed his residency in obstetrics and gynecology at Yale. His postdoctoral training included a fellowship in reproductive endocrinology and infertility, as well as, a fellowship in molecular biology, both at Yale.